In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

Additionally, HIMS has minimal debt levels, with a debt-to-equity ratio below 1%, and holds $300 million in cash, representing a 42% cash-to-assets ratio. These figures underscore HIMS' financial ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.